Principal Financial Group Inc. Has $46.97 Million Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Principal Financial Group Inc. lessened its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 4.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,573,356 shares of the specialty pharmaceutical company's stock after selling 71,695 shares during the period. Principal Financial Group Inc. owned approximately 4.90% of Collegium Pharmaceutical worth $46,965,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical in the fourth quarter worth about $230,000. Raymond James Financial Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth approximately $2,432,000. Amundi grew its position in Collegium Pharmaceutical by 188.3% in the fourth quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock worth $446,000 after buying an additional 10,168 shares during the last quarter. Kendall Capital Management increased its holdings in shares of Collegium Pharmaceutical by 31.6% in the fourth quarter. Kendall Capital Management now owns 17,760 shares of the specialty pharmaceutical company's stock valued at $509,000 after buying an additional 4,260 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after acquiring an additional 374 shares during the last quarter.

Collegium Pharmaceutical Stock Up 1.8%

COLL stock traded up $0.55 during midday trading on Monday, reaching $30.90. The company had a trading volume of 431,680 shares, compared to its average volume of 369,406. The company has a 50 day moving average of $29.22 and a two-hundred day moving average of $29.50. The company has a market capitalization of $992.82 million, a P/E ratio of 25.33 and a beta of 0.64. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a current ratio of 1.08, a quick ratio of 1.01 and a debt-to-equity ratio of 3.30.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same period in the previous year, the business posted $1.45 EPS. Collegium Pharmaceutical's revenue for the quarter was up 22.7% on a year-over-year basis. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of Collegium Pharmaceutical stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the sale, the director directly owned 70,658 shares in the company, valued at $2,163,547.96. The trade was a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.51% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on COLL. Wall Street Zen lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $43.75.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.